Tadalafil is a medication used to treat male sexual performance problems such as erectile dysfunction and enlarged prostate. It works by increasing blood flow to the genital area, thus helping to get and maintain erections.
Tadalafil is not a prostaglandin inhibitor like other agents that are used to treat Erectile Dysfunctions and unlike Sildenafil, it does not lead to the development of visual disturbances and sensory conditions. When Tadalafil is used for the treatment of ED, its duration of action can last to up to 36 hours which is longer than the action span of both Sildenafil and Vardenafil. Since PDE5 inhibitors only facilitate an erection as a response to sexual stimulation, Tadalafil’s longer duration of action generates a more spontaneous sexual stimulation and sexual action. According to the guidelines for the treatment of ED, PDE5 inhibitors should be considered as the first line of treatment before looking for additional options.
Tadalafil was approved by the FDA for the clinical treatment of ED in 2003 and for the treatment of Pulmonary Arterial Hypertension in 2009. Clinical studies in patients with PAH showed an improvement in the activity and exercise capacity of their system and a diminished medical worsening of this condition during the treatment. In 2011, Tadalafil was approved by the FDA for the management of the symptoms of Benign Prostate Hyperplasia and for a concurrent treatment of ED and BPH.
Your healthcare service provider needs to be informed if you are suffering from the following conditions: